Live

Endpoints NewsHouse committee directs FDA to speed up IND sign-off process FierceBiotechExecutive Interviews at Fierce Biotech Week 2026 BioWorldBiopharma money raised by month in 2026 (US$M)BioPharma DiveStudy data convince Lundbeck to push new migraine drug forward BioPharma DiveGeneric drugmakers gain key victory in ‘skinny label’ patent case Endpoints NewsInnovent declares Phase 3 success for ADC that attracted huge Takeda deal FierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection Clinical OMICsInfluenza Drugs Could Prevent Cognitive Decline in Chronic Viral Infections FierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery system PharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streak Promega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent Toolkit BioWorldNME Digest: Q1 2026

Lonza News 12. März 2026

Lonza divests Capsules & Health Ingredients business to Lone Star Funds for $3bn - Nutraceutical Business Review

Lonza divests Capsules & Health Ingredients business to Lone Star Funds for $3bn - Nutraceutical Business Review

Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.